Optimi Health Partnership with Numinus Wellness Provides Update on First All-Natural Psilocybin Protocol

VANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN)…

Numinus Wellness Q2 2021 Results Highlighted by $17.25 Million Financing, Mindspace Wellbeing Acquisition and Clinical Trial Collaboration with MAPS PBC

Events subsequent to quarter end include $40.25 million financing and Phase 1 clinical trial    VANCOUVER, BC, April 29, 2021 /CNW/…

Numinus Announces Phase 1 Clinical Trial of Natural Psilocybin Mushroom Extraction Prepared at Company Lab

Clinical trial will evaluate safety and psychoactive properties of natural Psilocybin product extracted and formulated at 7,000-square-foot…

Numinus to expand state-of-the-art psychedelics research laboratory

Numinus Bioscience adds research space, enhances contract services, accelerates IP development and increases psychedelic supply capacity VANCOUVER,…

Regulatory approvals place Numinus lab at the forefront of global psychedelics research

Numinus Bioscience adds Ketamine and LSD to licence to produce, assemble and sell a wide variety of…

Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update

VANCOUVER, BC, March 2, 2021 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an…

Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation

Trial enters pre-implementation stage having met several key milestones towards expanding access to patients with PTSD…

Numinus Wellness Completes Acquisition of Montreal-based Mindspace Wellbeing

Acquisition expands Numinus’ presence while improving psychedelic-assisted therapy landscape in Canada VANCOUVER, BC, Feb. 8, 2021 /CNW/ – Numinus Wellness…

Numinus Wellness Closes Q1 2021 with Strong Cash Position and Industry Firsts

Key milestones met in ongoing trials, expanding national footprint, and enhanced research capabilities ensure Numinus’ continued growth…

Numinus Wellness Forges Forward into Psychedelic Discovery Research with the Orbitrap Exploris 120 Mass Spectometer

Acquisition of industry-leading instrument by Thermo Fisher Scientific will significantly advance psychedelic research and accelerate third-party…

Numinus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic Products

The agreement will focus on developing safe, effective, all-natural products for the emerging psychedelic industry  VANCOUVER, BC, Jan.…

Numinus Announces Closing of $17 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option

Proceeds add to recently executed warrants and options of $8.9 million VANCOUVER, BC, Dec. 29, 2020 /CNW/ – Numinus…